TABLE 3.
Microbiological eradication at TOC according to primary diagnosis and baseline pathogen (ME population)
| Subgroup | Values for patients receiving: |
||
|---|---|---|---|
| Plazomicin at 10 mg/kg (n = 7) | Plazomicin at 15 mg/kg (n = 35) | Levofloxacin at 750 mg (n = 21) | |
| No. of patients with eradication at TOC/no. of patients with the following primary diagnosis (%): | |||
| AP | 2/2 (100) | 16/18 (88.9) | 12/15 (80.0) |
| 95% CI | 15.8–100 | 65.3–98.6 | 51.9–95.7 |
| cUTI | 4/5 (80.0) | 15/17 (88.2) | 5/6 (83.3) |
| 95% CI | 28.4–99.5 | 63.6–98.5 | 35.9–99.6 |
| No. of patients with eradication at TOC/no. of patients infected with the following pathogen at baseline (%): | |||
| Gram-positive bacteriaa | 1/1 (100.0) | 3/3 (100.0) | 1/1 (100.0) |
| Gram-negative bacteria | 5/6 (83.3) | 28/32 (87.5) | 16/20 (80.0) |
| E. coli | 3/4 (75.0) | 22/25 (88.0) | 12/16 (75.0) |
| K. pneumoniae | 1/1 (100.0) | 2/2 (100.0) | 1/1 (100.0) |
| Other Enterobacteriaceaeb | 1/1 (100.0) | 4/4 (100.0) | 3/3 (100.0) |
| P. aeruginosa | 0/0 (0.0) | 1/2 (50.0) | 0/0 (0.0) |
| No. of patients with eradication at TOC/no. of patients whose pathogen had the following MIC at baseline (%): | |||
| Plazomicin MIC ≤ 4 μg/ml | 5/6 (83.3) | 27/29 (93.1) | 16/19 (84.2) |
| Plazomicin MIC > 4 μg/ml | 0/0 (0.0) | 2/3 (66.7) | 1/1 (100.0) |
| Levofloxacin MIC ≤ 4 μg/ml | 4/4 (100.0) | 23/24 (95.8) | 15/16 (93.8) |
| Levofloxacin MIC > 4 μg/ml | 1/2 (50.0) | 5/7 (71.4) | 1/3 (33.3) |
a
Gram-positive bacteria included methicillin-susceptible Staphylococcus aureus (n = 1), Enterococcus faecalis (n = 3), and Staphylococcus saprophyticus (n = 1).
b
Other Enterobacteriaceae included Citrobacter freundii (n = 1), Enterobacter aerogenes (n = 1), M. morganii (n = 2), and P. mirabilis (n = 4).